According to Zacks, “I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China. “
A number of other analysts have also recently commented on the company. HC Wainwright reduced their price objective on I-Mab from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, March 30th. Piper Sandler reduced their price objective on I-Mab from $90.00 to $80.00 in a research report on Tuesday, March 29th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $84.43.
A number of large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in I-Mab by 0.3% during the first quarter. The Manufacturers Life Insurance Company now owns 479,503 shares of the company’s stock valued at $7,787,000 after purchasing an additional 1,500 shares during the period. Goldman Sachs Group Inc. grew its holdings in I-Mab by 98.3% during the first quarter. Goldman Sachs Group Inc. now owns 726,692 shares of the company’s stock valued at $11,801,000 after purchasing an additional 360,273 shares during the period. Wellington Management Group LLP bought a new stake in I-Mab during the first quarter valued at about $548,000. State Street Corp grew its holdings in I-Mab by 20.5% during the first quarter. State Street Corp now owns 751,254 shares of the company’s stock valued at $12,200,000 after purchasing an additional 127,890 shares during the period. Finally, Vident Investment Advisory LLC boosted its stake in shares of I-Mab by 30.0% in the first quarter. Vident Investment Advisory LLC now owns 28,602 shares of the company’s stock worth $464,000 after acquiring an additional 6,608 shares during the period. 96.17% of the stock is owned by institutional investors and hedge funds.
About I-Mab (Get Rating)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune.
- Get a free copy of the StockNews.com research report on I-Mab (IMAB)
- Short-Covering Begins In Big Lots
- Agilent Technologies Is Bottoming But Don’t Buy It Yet
- Institutions Ring The Register On Toll Brothers Stock
- Dick’s Sporting Goods Falls Flat On Weak Guidance
- Two Retailers, One To Buy And One To Avoid
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.